glp-1 obesity drugs news today 2025 Pharmacy Pricing Update (Dec 2025) Periodic Graphics: The science of

Healthcare utilization, mortality, and cardiovascular events following GLP1-RA initiation in chronic kidney disease

They can offer medical advice and create a plan that fits your health needs, goals, and access to care

Therefore, long-acting GLP-1 receptor agonists offer a viable treatment option for people with type 2 diabetes and effectively align with the ADAs standard of care recommendations by addressing more than just blood glucose levels

However, these drugs are known to cause a plethora of adverse effects such as weight gain, edema, intestinal discomfort and hypoglycemia (2)

Stable CHO-SNAP-GLP-1R and MIN6B1-SNAP-GLP-1R cells were generated by transfecting pSNAP-GLP-1R (Cisbio) into wild-type CHO-K1 (ECACC) or MIN6B1, G418 (1 mg ml 1 ) selection, and single-cell sorting by fluorescence-activated cell sorting (FACS) following SNAP-Surface-488 (New England Biolabs) labeling

October 15, 2025: 133 New Lawsuits Filed for Injuries from Zepbound and Other GLP-1 Drugs Between September and October 2025, 133 lawsuits joined the group litigation for people harmed by Zepbound and other GLP-1 drugs